CSL accuses ex-exec, now at Pharming, of stealing trade secretsCSL Behring has filed a lawsuit against a former employee, claiming he stole sensitive information with the intention Share XCSL accuses ex-exec, now at Pharming, of stealing trade secretshttps://pharmaphorum.com/news/csl-accuses-ex-exec-now-at-pharming-of-stealing-trade-secrets/
HAE patients get new option as NICE backs Takeda’s TakhzyroPatients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE Share XHAE patients get new option as NICE backs Takeda’s Takhzyrohttps://pharmaphorum.com/news/hae-patients-get-new-option-as-nice-backs-takedas-takhzyro/
FDA rejects Pharming’s Ruconest HAE label expansionThe FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for Share XFDA rejects Pharming’s Ruconest HAE label expansionhttps://pharmaphorum.com/news/fda-rejects-pharmings-ruconest-hae-label-expansion/
Shire eyes blockbuster sales as FDA approves HAE therapyThe FDA has approved Shire’s first antibody-based preventive treatment for the rare disease hereditary angioedema, raising hopes for Share XShire eyes blockbuster sales as FDA approves HAE therapyhttps://pharmaphorum.com/news/shire-eyes-blockbuster-sales-as-fda-approves-hae-therapy/
Shire plans filing for HAE drug after phase 3 successLanadelumab could revolutionise treatment of swelling disease. Share XShire plans filing for HAE drug after phase 3 successhttps://pharmaphorum.com/news/shire-plans-filing-hae-drug-phase-3-success/